Skip to main content

Table 3 Results of Antibody Measurement

From: Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study

Subject number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Cancer Esoph. CCA Rectal Esoph. CCA Pancr. Gist Colon CCA Coecum
+Ovar.
Pancr. Pancr. Bile duct Rectal Bile duct pCCC
Surgery blood (mL)
Dilution fluid (mL)
1400
550
500
0
2800
2500
1600
1000
1100
500
1600
500
800
300
950
300
1000
700
2200
200 + 800
800
150
1700
1400
1661
900
2600
50
1400
100
800
200
EC after LDF, residual Ab (pg/mL) BLQ 1694 BLQ BLQ 205.0 BLQ 1026 491.0 ND 252.0 BLQ 888.0 628.0 BLQ 160.0 BLQ
Ab total (ng) BLQ 69.0 BLQ BLQ 13.0 BLQ 68.0 22.0 BLQ 27.0 BLQ 59.0 26.0 BLQ 9.0 BLQ
Vol. EC (mL) 142.0 76.0 150.0 98.0 97.0 187.0 101.0 80.0 70.0 141.0 75.0 101.0 77.0 373.0 133.0
Vol. EC post LDF (mL) 107.0 41.0 115.0 63.0 62.0 152.0 66.0 45.0 35.0 106.0 40.0 66.0 42.0 320.0 60.0 200.0
Amount of applied antibody (μg) 5.0 2.5 2.5 2.5 2.5 5.0 2.5 2.5 5.0 2.5 5.0 5.0 5.0 2.5 2.5
  1. BLQ Below the limit of quantification of 125 pg/mL
  2. Ab Antibody, CCA cholangiocarcinoma, EC Erythrocyte concentrate, Esoph. Esophageal cancer, LDF Leukocyte depletion filter, ND No antibody detectable in the reservoir, Ovar. Ovarian cancer, Pancr. Pancreatic cancer, pCCC Perihilar cholangiocellular carcinoma, Vol. Volume